Mycobutin (rifabutin)
- Forms
- Capsule
- Strengths
- 150 mg
- Area
- Tuberculosis;Acquired Immunodeficiency Syndrome
- Alternatives
- Yes, in some Member States
What is this? Mycobutin is a medicine in capsules. It helps treat tuberculosis and some infections in people with weak immune systems.
What's happening? There is a shortage of Mycobutin capsules in the EU. Other similar medicines may be available.
Does this affect me? If you take Mycobutin, your supply may be affected. Check with your pharmacist.
What should I do? Ask your pharmacist or doctor about other options. Do not stop taking your medicine without advice.
🤖 To jest automatycznie generowane streszczenie w języku prostym na podstawie oficjalnego komunikatu agencji, przy użyciu AI. Ma charakter wyłącznie informacyjny — nie stanowi porady medycznej. W kwestiach dotyczących Twojego zdrowia zawsze konsultuj się z farmaceutą lub lekarzem oraz zapoznaj się z oficjalnym źródłem zamieszczonym poniżej.
📋 Z oficjalnego komunikatu organu
Zaktualizowano 3 tygodnie temu- Pierwsza publikacja
- 30/06/2026
- Leki objęte
- Mycobutin (rifabutin)
- Słabości dotknięte
- 150 mg
- Oczekiwana rozdzielczość
- Expected to resolve by November 2026
- Status niedoboru
- Shortage ongoing
- Obszar terapeutyczny (MeSH)
- TuberculosisAcquired Immunodeficiency Syndrome
- Dostępność alternatyw
- Yes, in some Member States
- Postacie farmaceutyczne objęte
- Capsule
Zawartość strony
- Shortage information
- Key facts
- Key dates
- Related medicine information
Braki w dostawie
There is a shortage of Mycobutin in EU/EEA countries.
Mycobutin is a medicine for the prevention and treatment of Mycobacterium avium complex infections, often in AIDS patients, and the treatment of tuberculosis (TB).
The company that supplies Mycobutin is experiencing manufacturing issues, as a supplier has stopped production of the starting material rifamycin S, used to produce the active substance rifabutin. This has led to a shortage of Mycobutin. The shortage is not related to a quality defect of the product or a safety issue.
The shortage is expected to last until at least November 2026.
The shortage affects all Member States where the product is marketed: Austria, Belgium, Czechia, Finland, Germany, Ireland, Italy, Luxembourg, the Netherlands, Portugal, Spain and Sweden.
This information may change. For up-to-date information about the status of a medicine shortage in a particular Member State, consult the national shortage register or contact the national competent authority using the below links.
EMA’s Executive Steering Group on Shortages and Safety of Medicinal Products (MSSG) and EMA’s shortages working party (Medicines Shortages Single Point of Contact – SPOC - working party) are closely monitoring the supply situation and engaging with the marketing authorisation holder to mitigate the impact of the supply shortage.
The company has contracted another supplier of rifamycin S and is taking the necessary steps to have the supplier registered and authorised. Regulatory support is being provided by the National Competent Authorities.
The SPOC Working Party supports EMA’s MSSG and monitors and reports events that could affect the supply of medicines in the EU.
- There is an ongoing shortage of Mycobutin in EU/EEA countries, which is expected to last until at least November 2026.
- For additional information consult your country’s shortage register or contact your national competent authority.
- There is an ongoing shortage of Mycobutin in EU/EEA countries, which is expected to last until at least November 2026.
- If Mycobutin is not available, your doctor will discuss with you alternatives such as switching to a different medicine, where available.
- If you have any questions, speak to your doctor or pharmacist.
- For additional information, consult your country’s shortage register or contact your national competent authority using the below links.
Powód niedoboru
The company that supplies Mycobutin is experiencing manufacturing issues, as a supplier has stopped production of the starting material rifamycin S, used to produce the active substance rifabutin. This has led to a shortage of Mycobutin. The shortage is not related to a quality defect of the product or a safety issue.
The shortage is expected to last until at least November 2026.
Państwa członkowskie objęte
The shortage affects all Member States where the product is marketed: Austria, Belgium, Czechia, Finland, Germany, Ireland, Italy, Luxembourg, the Netherlands, Portugal, Spain and Sweden.
This information may change. For up-to-date information about the status of a medicine shortage in a particular Member State, consult the national shortage register or contact the national competent authority using the below links.
Monitorowanie niedoborów
EMA’s Executive Steering Group on Shortages and Safety of Medicinal Products (MSSG) and EMA’s shortages working party (Medicines Shortages Single Point of Contact – SPOC - working party) are closely monitoring the supply situation and engaging with the marketing authorisation holder to mitigate the impact of the supply shortage.
The company has contracted another supplier of rifamycin S and is taking the necessary steps to have the supplier registered and authorised. Regulatory support is being provided by the National Competent Authorities.
The SPOC Working Party supports EMA’s MSSG and monitors and reports events that could affect the supply of medicines in the EU.
Zalecenia dla pracowników służby zdrowia
- There is an ongoing shortage of Mycobutin in EU/EEA countries, which is expected to last until at least November 2026.
- For additional information consult your country’s shortage register or contact your national competent authority.
Zalecenia dla pacjentów i opiekunów
- There is an ongoing shortage of Mycobutin in EU/EEA countries, which is expected to last until at least November 2026.
- If Mycobutin is not available, your doctor will discuss with you alternatives such as switching to a different medicine, where available.
- If you have any questions, speak to your doctor or pharmacist.
- For additional information, consult your country’s shortage register or contact your national competent authority using the below links.
Kluczowe informacje
- Medicines affected
- Mycobutin (rifabutin)
- Supply shortage status
- Shortage ongoing
- Therapeutic area (MESH)
- Tuberculosis
- Acquired Immunodeficiency Syndrome
- Pharmaceutical forms affected
- Capsule
- Strengths affected
- 150 mg
- Availability of alternatives
- Yes, in some Member States
Kluczowe daty
- Expected resolution
- Expected to resolve by November 2026
- First published
Informacje dotyczące medycyny
🔬 Szczegóły medyczne / techniczne dla specjalistów
Forms: Capsule · Strengths: 150 mg · Area: Tuberculosis;Acquired Immunodeficiency Syndrome · Alternatives: Yes, in some Member States
Wszystkie informacje na tej stronie pochodzą z oficjalnego komunikatu agencji. Tłumaczymy i podsumowujemy je; nie dodajemy ani nie zmieniamy faktów.